HealthSnap closed a $25 million Series B funding round led by Sands Capital. The Miami-based company seeks to help providers better care for a rapidly aging and chronically ill population through its remote patient monitoring platform.
Turquoise Health closed a $30 million Series B round, which brings its total funding to date to $55 million. The San Diego-based startup, which has more than 160 customers, sells a platform that makes it easier for hospitals and payers to comply with price transparency regulations.
Armed with fresh capital, Nava Benefits hopes to take advantage of what it believes will be a disruption in the way smaller businesses approach health and wellness benefits, including the many digital tools now on the market.
Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company's technology and growth of its commercial use cases.
VirtualHealth founder and CEO Adam Sabloff said the company is not disclosing the dollar amount of the round at this time but noted that the financing round brings the total amount raised by VirtualHealth to more than $25 million.
GreatPoint Ventures led the Series B round for the San Francisco-based startup, and Tarsadia Investments, Crosslink Capital and Uncork Capital also participated.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Polaris Partners led the Series B round, and Ignition Partners, Osage University Partners, Mindset Ventures and UL Ventures also participated.
Black Granite Capital led the round, which the company, Jump Technologies, will use to expand its sales efforts and support product development.
The startup will use the money from Insight Venture Partners and Atomico for R&D, to further expand its reach in the MSK field and to grow its commercial team.
The Series B round, which Innovaccer will use to continue developing its InData platform, was led by Westbridge Capital. Lightspeed Ventures also participated.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Baltimore, Maryland-based startup Protenus has raised $11 million in a Series B round led by Kaiser Permanente Ventures and F-Prime Capital Partners. Arthur Ventures, LionBird Venture Capital and Cognosante Ventures also participated.
This one’s a hair better than, ah, the hair of the dog: Aldea Pharmaceuticals’ drug for acute alcohol intoxication is advancing into clinical trials, thanks to a sizable new round of funding. The new drug’s meant to be intravenously administered to emergency room patients with alcohol poisoning. The company just closed out a $24 million Series […]
The burgeoning cancer immunotherapy space has tons of investors, to be sure, but perhaps no other startup has ever been as well-capitalized as Seattle-based Juno Therapeutics. The company now has raised $310 million in the past year, having just closed a $134 million Series B round that comes right on the heels of its $176 million […]
Thermalin Diabetes is picking up steam – and funding – as it develops a more concentrated and faster-acting version of insulin. The Boston and Cleveland-based company just raised $5.9 million from private investors in the first tranche of a Series B round. To date, it has raised about $15 million in equity and $8 million in NIH […]
